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Abstract
Background—Candida is a leading cause of infection in infants on extracorporeal membrane 
oxygenation (ECMO). Optimal micafungin dosing is unknown in this population because ECMO 
can alter drug pharmacokinetics (PK).
Methods—To characterize micafungin PK and safety in infants on ECMO, we conducted an 
open label PK trial. Infants on ECMO either received IV micafungin 4 mg/kg/day for invasive 
candidiasis prophylaxis, or 8 mg/kg/day when a fungal infection was suspected or confirmed. We 
collected plasma samples after single and multiple micafungin doses. We defined the therapeutic 
target as the adult exposure associated with efficacy in Phase III trials, and the prophylactic target 
as one-half of the therapeutic target.
Results—We enrolled 12 infants (124 samples) with a median age of 59 days. Using a 1-
compartment model, median weight-normalized volume of distribution and clearance were 0.64 
L/kg and 0.041 L/kg/h, respectively. Dose-exposure simulations revealed that doses of 2.5 and 5 
mg/kg/day matched exposure targets for prophylaxis and treatment of invasive candidiasis, 
respectively. We did not observe any drug-related adverse events.
Conclusions—In infants on ECMO, micafungin volume of distribution was higher and 
clearance was in the upper range of previously published values for infants not on ECMO. Based 
on these data, we recommend dosing of 2.5 and 5 mg/kg/day for prophylaxis and treatment of 
invasive candidiasis, respectively, to match adult exposure proven effective against Candida spp.
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Introduction
Extracorporeal membrane oxygenation (ECMO) provides respiratory and cardiac support in 
critically ill infants when conventional modes of life-support fail.1 Although potentially life-
saving, ECMO support is associated with a high risk of nosocomial infections in children 
(8-16%).2 The most common cause of ECMO-related nosocomial infection in infants and 
children and the second most common cause in neonates is invasive candidiasis.2 Invasive 
candidiasis causes high rates of morbidity and mortality and is difficult to treat because of 
the organism’s ability to form biofilms on indwelling catheters.3 For this reason, 
recommended treatment of invasive candidiasis consists of both antifungal therapy and 
removal of indwelling catheters.4,5 However, catheter removal for children on ECMO is 
impossible; therefore, therapy relies upon optimal dosing of antifungal agents.
Micafungin is an attractive antifungal drug in infants on ECMO because it is fungicidal 
against a broad spectrum of Candida spp, and can penetrate biofilms.6-8 However, the 
optimal dosing of micafungin remains to be established in the setting of ECMO because 
ECMO support can alter drug pharmacokinetics (PK).9,10 In infants on ECMO, the volume 
of distribution (V) of drugs typically increases due to the large volume of blood required to 
prime the ECMO circuit, disease state (e.g., inflammation, anasarca), and drug adsorption by 
the ECMO circuit itself.9-13 Clearance (CL) of drugs can be affected by the organ 
dysfunction commonly observed in infants on ECMO, as well as non-specific drug 
extraction by the circuit itself. Micafungin may be more vulnerable to adsorption by the 
circuit because it is highly protein bound (>99%).14 Therefore, it is likely that current 
micafungin dosing recommendations for treatment (2-3 mg/kg every 24h) are inadequate for 
infants on ECMO.15 In this open-label PK trial, we determined micafungin PK in infants on 
ECMO and compared the resulting micafungin exposure to adult exposures known to be 
effective against invasive candidiasis.
Materials and Methods
Design and study population
This was a prospective, open-label, PK and safety study of micafungin conducted at Duke 
University Medical Center. We enrolled infants (0-2y) supported with ECMO, excluding 
those with a history of echinocandin allergy. Infants without fungal infection were enrolled 
in the prophylaxis arm and received IV micafungin per study protocol (4 mg/kg every 24h, 
infused over 1h). Infants with suspected or confirmed fungal infections who were prescribed 
micafungin per standard of care, were enrolled in the treatment arm and dosing was adjusted 
per study protocol to 8 mg/kg every 24h, infused over 1h. Duration of micafungin 
prophylaxis was up to 8 days, whereas duration of therapy in the treatment arm was 
determined by the treating physician. Because micafungin is light-sensitive, drug vials and 
infusion bags were protected from light.16 However, the ECMO circuit is not protected from 
light, so it is possible that micafungin in the blood was exposed to light while transiting the 
ECMO circuit. This trial was approved by the institutional review board of Duke University 
Medical Center, registered with clinicaltrials.gov (NCT01666769), and conducted under a 
Food and Drug Administration investigational new drug application (No.115255). Written 
informed consent was obtained from the legal guardian of each infant.
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PK sampling
We collected up to 14 plasma PK samples (200 µL of whole blood per sample) around dose 
1 and 4 via a peripheral arterial catheter. Sampling intervals were as follows (1 sample per 
interval): 0-4h before the start of infusion, and 0-30 min, 60-90 min, 2-4h, 8-10h, 12-16h, 
and 22-24h after the end of micafungin infusion. Samples were collected in 
ethylenediaminetetraacetic acid microcontainers and processed immediately or placed on ice 
(<30 minutes) until processing. Plasma was separated via centrifugation (3000g for 10 
minutes at 4°C), manually aspirated and transferred to polypropylene tubes. Plasma samples 
were frozen at –20°C for a maximum of 24h, and stored at −80°C until analysis. PK samples 
were protected from light when stored in the freezer. No special precautions were 
undertaken during processing of samples because reconstituted micafungin was shown to be 
stable up to 24 hours at room temperature when exposed to light.16
ECMO Circuit Configuration
Two types of ECMO circuits were used; S3 and CardioHelp (see figure, Supplemental 
Digital Content 1). A hemofilter (Sorin DHFO.2, Sorin Group, Milan, Italy) was used in 
infants requiring hemofiltration. The prime volume for each circuit was 450mL and included 
packed red blood cells (350mL), fresh frozen plasma (50mL), Plasmalyte® crystalloid 
(50mL), sodium bicarbonate (25mEq), and heparin (100units).
PK analysis
Plasma micafungin concentrations were determined using a validated high performance 
liquid chromatography assay with fluorescent detection.17 The lower limit of quantification 
was 0.05 mg/L. Intraday precision ranged from 1.28% for the highest concentration of the 
standard curve (25.00 mg/L) to 17.90% for the lowest concentration (0.05 mg/L). Interday 
precision ranged from 3.27% to 14.41% within the concentration range of the standard curve 
(0.05–25.00 mg/L).
Primary outcomes were micafungin CL and V. PK data were analyzed by nonlinear 
regression with the most appropriate model using Winonlin v6.3 (Pharsight Co., St. Louis, 
MO). The model fit was evaluated using successful minimization, diagnostic plots, goodness 
of fit as assessed by the Akaike Information Criterion and precision of the parameter 
estimates. We assessed systemic exposure by estimating area under the concentration-time 
curve from 0 to 24h (AUC0–24) after the 1st and the 4th dose. AUC0–24 was computed by the 
linear up log down trapezoidal method using observed data. We assessed the relationship 
between PK parameters and covariates potentially affecting micafungin disposition (age, 
serum albumin, aspartate aminotransferase, total bilirubin, and duration of ECMO support) 
by visual inspection of scatter plots.18-20 Finally, we explored the relationship between PK 
parameters and the number of doses (single vs multiple doses), and the presence of the 
hemofilter in the ECMO circuit, using a Wilcoxon rank-sum test.
Assessment of dose-exposure relationship
For a target efficacy exposure, we used an AUC0-24 range of 75-139 mg*h/L as a surrogate 
pharmacodynamic (PD) end point.19,21 This endpoint matches the micafungin exposure 
achieved by adult participants who cleared their fungal infection in the large, phase III 
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efficacy trial.22 There is no established target exposure for Candida prophylaxis, however, 
IV micafungin 50 mg (1 mg/kg in children) daily was proven effective in preventing fungal 
infections in 882 adults and children undergoing hematopoietic stem cell transplantation.23 
Because micafungin PK is linear in this dosing range, the prophylactic exposure target was 
set to 50% of the therapeutic target (37.5-69.5 mg*h/L).19,21,24
In order to characterize micafungin exposure, we simulated a variety of dosing regimens and 
measured the proportion of infants in our population who achieved the therapy and 
prophylaxis exposure targets after the 1st and 4th micafungin dose. Simulations were 
performed by estimating the maximum (Cmax) and minimum (Cmin) micafungin 
concentrations for each individual for the first dosing interval and at steady state using the 
equation for an intermittent infusion with the individual parameter estimates from the final 
model. We then used the predicted Cmax and Cmin values to calculate the AUC for the dosing 
interval from 0 to 24h and at steady state using the equations for the linear-up log-down 
trapezoidal approach.
Safety
The secondary outcome was the proportion of infants experiencing adverse events (AEs). 
AEs were defined as any untoward medical occurrence whether or not considered drug-
related during the conduct of the clinical trial. AEs were recorded while on study drug and 
for 7 days after the last study dose of micafungin. Liver toxicity and hypokalemia were the 
AEs of special interest because they were described previously in 3% and 2% of infants and 
children receiving micafungin, respectively.21 Levels of serum aspartate aminotransferase, 
alanine aminotransferase and potassium were therefore measured at baseline (within 72h 
prior to the first study dose), and at the end of the study (within 72h after the last study 
dose). Other laboratory determinations were recorded from consent through 72h after the 
last study dose, if performed per standard of care. Other laboratory determinations included 
albumin, blood urea nitrogen, serum creatinine, sodium, complete blood count and 
microbiology culture results. The safety data were summarized descriptively. We used 
STATA 13 (College Station, TX) to perform the statistical analyses.
Results
We enrolled 12 infants on ECMO support with a median (range) postnatal age of 59 days (0, 
574) (Table 1). Two infants were born preterm (27 and 34 weeks of gestational age [GA]) 
and were 122 and 187 days postnatal age at time of enrollment, respectively. Infants were 
supported by ECMO for a median time of 4 days (2, 10) before the first micafungin dose. Of 
the 12 infants, 11 (92%) received prophylactic intravenous (IV) micafungin (4 mg/kg every 
24h) for 4 (2, 8) days. One infant (ID # 2) was treated for presumed fungal infection with IV 
micafungin (8 mg/kg every 24h) for 6 days. Site of drug administration included central 
venous catheter (n=7) and ECMO circuit, post-oxygenator (n=1). Site of drug administration 
was not recorded for 4 infants. All 11 infants from the prophylactic group had PK samples 
collected around dose 1, and 5/11 (45%) of these infants remained on micafungin long 
enough to complete sampling around dose 4. The one infant in the therapeutic group had PK 
samples collected around doses 2 and 5. PK samples were collected from a peripheral 
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arterial line in all infants but one for whom site of PK sampling was not recorded. 
Hemofiltration was used in 4/12 (33%) infants (Table 2).
Pharmacokinetics
We collected a total of 124 plasma samples, with a median of 11 (6, 14) samples per infant. 
Plasma concentration-time profiles are shown in Figure 1. A 1-compartment model with 
zero-order infusion appropriately fit the data (Table 2). PK parameters were estimated with 
high precision as evidenced by median CL and V coefficient of variation of 6% (5, 14) and 
11% (8, 14), respectively. Three/124 (2%) PK samples were excluded from the analysis; one 
concentration was below the lower limit of quantification (subject ID#5), and 2 plasma 
samples lacked confirmation of sampling time (Subject ID#12). PK parameter estimates did 
not change when these 3 concentrations were removed from the analysis. Median [95% 
confidence interval] CL decreased over the study period from 0.04 L/kg/h [0.03, 0.05], to 
0.02 L/kg/h [0.02, 0.03] after single and multiple doses, respectively. Median [95% CI] V 
was 0.62 L/kg [0.53, 0.73) and 0.52 L/kg [0.31, 0.67] after a single and multiple doses, 
respectively.
We did not observe a significant difference in CL between infants with and without a 
hemofilter in the circuit (median [range] CL of 0.04 L/kg/h [0.03, 0.04] vs 0.04 L/kg/h [0.03, 
0.06], respectively, p=0.50) nor did we observe a significant relationship between V and the 
presence of a hemofilter (0.54 L/kg [0.46, 0.75] and 0.67 L/kg [0.44, 0.98] in infants with 
and without a hemofilter, respectively; p=0.17). In evaluating other covariates of interest, we 
observed an inverse correlation between CL and age, with older infants demonstrating lower 
CL per kg of bodyweight (see figure, Supplemental Digital Content 2). The same 
relationship also was observed for V and age where older infants had lower V per kg of 
bodyweight (see figure, Supplemental Digital Content 2). An inverse relationship also was 
observed between CL and serum albumin; subjects with low serum albumin had higher CL 
(see figure, Supplemental Digital Content 2). However, no relationship was observed 
between V and serum albumin, or between CL and the following covariates: AST, serum 
creatinine, or total bilirubin (data not shown). Finally, no relationship was observed between 
duration of ECMO support and CL or V (data not shown).
Dose-exposure relationship
Prophylactic arm (4 mg/kg IV every 24h)—Median AUC0-24 were 74 mg*h/L (53, 
106) and 117 mg*h/L (84, 187) after dose 1 and 4, respectively (Figure 2). After a single 
dose, all infants were at or higher than the prophylaxis range (Figure 2). After dose 4, all 
infants sampled (5/5) exceeded the prophylactic range. Although infants in the prophylactic 
arm were not treated for active fungal infection, 5/11 (45%) achieved the therapeutic 
exposure target (75-139 mg*h/L) after a single dose, while the remaining infants were below 
the lower limit of the therapeutic exposure target (Figure 2). Among the 5 infants who were 
sampled around dose 4, 3/5 (60%) were within the therapeutic range, and 2 were 
supratherapeutic. Four infants had a hemofilter in line (Table 2). When a hemofilter was in 
line, all infants (4/4) achieved AUC0-24 within or above the prophylactic target range after 
dose 1 and 4. Two/4 (50%) infants with a hemofilter achieved AUC0-24 within or above the 
therapeutic target range after dose 1 and 4.
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Treatment arm (8 mg/kg IV every 24h)—The one infant (ID#2) who received 
micafungin for suspected Candida infection had AUC0-24 of 213 and 178 mg*h/L after 
doses 2 and 5, respectively. This infant achieved an AUC0-24 that exceeded both 
prophylactic and therapeutic target ranges after doses 2 and 5 (Figure 2).
Dose-exposure simulations—A daily dose of 2.5 mg/kg infused over 1 h achieved the 
prophylactic target (AUC0-24 of 37.5 - 69.5 mg*h/L) within 24 h in 100% of the cohort. At 
steady state all children achieved an AUC0-24 of at least 37.5 mg*h/L, with 3 (25%) above 
the target range (AUC0-24 of 84, 88, 94 mg*h/L).
A daily dose of 5 mg/kg infused over 1 h achieved the therapeutic target range (AUC0-24 of 
75 - 139 mg*h/L) within 24 h in 100% of the cohort. At steady state all children achieved an 
AUC0-24 of at least 75 mg*h/L, with 3 (25%) above the target range (AUC0-24 of 169, 177, 
189 mg*h/L).
Safety
Five infants died during the study period. None of the deaths were considered related to 
micafungin. Two infants died following severe intracranial hemorrhage in the setting of 
systemic anticoagulation with heparin while on ECMO, and 1 died of refractory pulmonary 
hypertension after ECMO decannulation. Three additional AEs, unrelated to micafungin, 
were observed in 2 infants; 1 infant had severe intracranial hemorrhage but survived, and 
another had necrotizing enterocolitis likely related to prematurity and anticoagulation 
resulting in mild gastrointestinal bleeding.
Discussion
This is the first PK trial of micafungin in infants supported with ECMO. Infants on ECMO 
had altered PK requiring higher doses to achieve the same exposure as historical controls not 
on ECMO.15,19,24-26 We suggest an alternate dosing regimen of 2.5 and 5 mg/kg/day for 
prophylaxis and treatment of invasive candidiasis, respectively. However, preterm neonates 
at high risk for hematogenous Candida meningoencephalitis should be excluded from this 
recommendation because we did not evaluate the higher dosages (e.g., 10mg/kg) usually 
recommended in this populations.27,28
The V of micafungin in our cohort was 20-90% higher than that reported in infants not on 
ECMO (0.34 – 0.54 L/kg).15,25 There are three probable explanations for the increased V: 1) 
the large volume of blood required to prime the ECMO circuit (~450mL) relative to an 
infant’s native blood volume (80 mL/kg); 2) direct adsorption of micafungin by components 
of the ECMO circuit,12-14 and 3) altered physiology (e.g., anasarca, inflammation) 
commonly seen in critically ill infants. The impact of the ECMO prime volume is most 
pronounced in smaller infants where an infant’s circulating blood volume may be doubled or 
even tripled. Because the impact of prime volume is directly related to the ratio between 
prime volume and native blood volume, our results should not be extrapolated to older 
children where the ratio of exogenous (450 mL) to native blood volume (~2000-5000 mL) is 
much lower. Our findings are consistent with previous literature reporting increased V due to 
the ECMO prime volume in infants on fluconazole, vancomycin and gentamicin.10,18,20,29-32
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Drug adsorption to the ECMO circuit itself, which is well described in ex vivo studies, is 
also likely to contribute to the increase in V. Drug characteristics including lipophilicity and 
high protein binding are key factors driving adsorption.13,14 While micafungin is not 
lipophilic (logP −1.5), it is >99% protein bound.33 Other drugs with comparable protein 
binding and logP such as caspofungin were substantially adsorbed (56%) in an isolated ex 
vivo ECMO circuit.14 Preliminary results from a micafungin ECMO ex vivo study 
conducted by our group showed that micafungin concentrations dropped by 58% over 24h 
(Watt unpublished data). In summary, our study was not designed to isolate the source of 
altered V, but the increase in V was probably due to a combination of circuit prime volume, 
circuit adsorption of drug, and patient disease state.
In the current study, total CL after the first dose (0.041 L/kg/h [0.026, 0.062]) was in the 
upper range of previously reported values for infants not supported by ECMO (0.020-0.039 
L/kg/h).19,24-26 The increase in CL may be explained by altered drug metabolism. 
Micafungin is excreted primarily unchanged into bile and feces (71%) via hepatic 
transporter proteins.34 Limited metabolism also occurs in the liver by arylsulfatase and 
catechol-O-methyltransferase into metabolites with little or no antifungal activity.15 While 
the impact of ECMO on renal dysfunction is well described,35 the effect of ECMO on 
hepatic transporters and metabolic capacity is unknown. Micafungin PK studies in adults 
with severe hepatic dysfunction, revealed lower micafungin exposure and higher CL 
compared with healthy controls.36,37 This phenomenon was attributed to lower albumin 
concentrations in adults with hepatic dysfunction, resulting in higher availability of the 
unbound fraction to be cleared. In our cohort, no subjects had hepatic dysfunction, but 
critically ill infants on ECMO typically have serum albumin concentrations in the lower 
range of normal. In our study, we did observe an inverse relationship between clearance and 
serum albumin (see figure, Supplemental Digital Content 2), with a higher micafungin CL in 
infants who had low serum albumin. Finally, we did not find a relationship between PK 
parameters and serum creatinine. This is consistent with previous literature and the product 
label that states no adjustment is necessary for renal dysfunction.15,36
Higher apparent micafungin elimination with ECMO may also be due to non-specific and 
irreversible drug adsorption by the circuit if adsorption is an ongoing process.12-14 As 
described above, substantial extraction was observed over 24h in ex vivo circuits (58%).12 
The origin of this loss is still under investigation but could be due to circuit adsorption. It 
could also be explained by light degradation because micafungin is light-sensitive and the 
ECMO circuit is not protected from light, as opposed to drug vials and infusion bags.
The type of ECMO support could also impact micafungin disposition. Veno-venous ECMO, 
in which blood is drained and returned to the venous system via a single, double lumen 
cannula, is subject to a recirculation phenomenon. In recirculation, a portion of the 
oxygenated blood returned to the venous system is immediately taken back into the ECMO 
circuit via the drainage lumen of the cannula.38 The impact of recirculation on drug PK is 
unknown. However, this phenomenon increases the time drug spends in the circuit; and for 
drugs that are adsorbed by the circuit, this could decrease exposure (AUC). In our cohort, 
only 1 infant (ID #6) was on VV ECMO and had a high CL and a low AUC0-24h compared 
to the rest of the cohort. In veno-arterial (VA) ECMO deoxygenated blood is drained from 
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the venous system and pumped directly to the arterial circulation, completely bypassing the 
heart and lungs. The return flow is non-pulsatile. Non-pulsatile blood flow may be 
associated with reduced renal function, but its impact on a drug cleared by transporters in the 
liver such as micafungin is unknown.39
PK changes described above translated into micafungin exposure within or above the 
prophylaxis target range for infants who received 4 mg/kg/day. Thus, a dose 4 mg/kg/day 
may be too high for prophylaxis. However, assuming linear micafungin PK, standard 
prophylaxis dosing (1 mg/kg/day) recommended for older children would likely result in 
underexposure in infants on ECMO.15,21,23,24 Based on the dose-exposure simulations in 
our cohort, a dose of 2.5 mg/kg/day appears to be the most appropriate dose for Candida 
prophylaxis. Although simulations showed that some children will likely become 
supratherapeutic on 2.5 mg/kg/day, we believe that it is better to err on the higher side of 
exposure for two reasons: 1) invasive candidiasis is exceedingly difficult to treat in this 
population and 2) the highest simulated exposure on 2.5 mg/kg/day (94 mg*h/L) was well 
below the mean (standard deviation) exposure of 438 mg*h/L (99) that was deemed safe in a 
neonatal trial of 15 mg/kg/day.26 This dosing regimen needs to be prospectively evaluated.
The one infant who received micafungin 8 mg/kg/day for suspected Candida infection 
achieved AUC0-24 above the therapeutic target range, and survived until hospital discharge. 
Based on these findings, and on dose-exposure simulations performed in all infants of the 
cohort, we recommend a dose of 5 mg/kg/day for invasive candidiasis therapy. Dose-
exposure simulations were performed in all infants because PK is linear in this dosing 
range.21,40 On 5 mg/kg/day some children may achieve exposures exceeding the target 
range. Similar to the prophylactic regimen, we feel it is better to target higher exposure 
because these exposures are still in a “safe” range; and higher exposures may be needed to 
treat through potential fungal biofilms. Moreover, target exposure used in this study, was 
derived from a phase III efficacy study in which >85% of adults had their central catheter 
removed during candidemia treatment.22 In the setting of ECMO, removal of catheter is 
impossible and therefore, micafungin exposure required to clear the infection may be higher. 
This dosing regimen also needs prospective validation.
Although dosing in the current study was higher than recommended in term infants not on 
ECMO, micafungin had a favourable safety profile without any observed drug-related AEs. 
This is consistent with previous literature describing the safe use of micafungin up to 15 
mg/kg/day in young preterm infants.26 Safety assessment is however limited by our small 
sample size.
Our study is the first PK trial of micafungin in infants supported by ECMO. Because our 
study population includes vulnerable infants, enrollment was challenging and resulted in a 
limited sample size. In spite of the small sample size and critical illness of our population, 
interindividual variability in PK parameters was as expected. Other factors may affect 
micafungin PK in this population, including transfusion of blood products which we did not 
collect. Our data were also limited by the lack of documentation of site of drug 
administration in 4 infants. However, the effect of site of drug administration on PK is 
unknown, and PK parameters of those 4 infants (ID #5; 8-10) were similar to those with 
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complete documentation. Site of PK sampling was also lacking in 1 infant (ID #5), but our 
protocol did not allow drawing PK samples from site of drug administration. Therefore we 
do not expect any significant impact on PK results. Finally, our assessment of the ECMO 
impact on micafungin PK was limited by the lack of controls.
Conclusion
In this cohort of infants supported by ECMO, micafungin was well tolerated and the PK 
model indicated that V was higher and CL was in the upper range of what had been 
described previously in infants not on ECMO. In order to match exposure observed in 
adults, we recommend dosing of 2.5 and 5 mg/kg/day for prophylaxis and treatment of 
invasive candidiasis, respectively. These dosing regimens need prospective validation.
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Figure 1. Micafungin Concentration-Time Profiles*
*All subjects received IV micafungin 4 mg/kg every 24h, except for subject ID #2 who 
received 8 mg/kg every 24h
Subject ID # 2: PK samples were collected around dose 2 and 5
Subject ID # 12: The fourth dose was given 79h after the first dose, instead of 72h.
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Figure 2. Micafungin Exposure
AUC: Area under the concentration-time curve 0-24h
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Table 1
Clinical Characteristics*
N=12
Age (days) 59 (0.0, 574)
Gestational age (weeks) 39 (27, 39)
Weight (kg) 3.7 (2.9, 9.6)
Birth weight (kg) 3 (2.4, 4.3)
Male, n (%) 5 (42)
Race, n (%)
White 6 (50)
African American 6 (50)
Diagnosis, n (%)
Cardiomyopathy 4 (34)
Pulmonary hypertension 3 (25)
Congenital heart disease 3 (25)
Congenital diaphragmatic hernia 1 (8)
Respiratory failure 1 (8)
Serum creatinine (mg/dL)† 0.5 (0.2, 1.6)
ECMO support, n (%)
Veno-arterial 11 (92)
Veno-venous 1 (8)
ECMO circuit configuration, n (%)
S3 8 (67)
Cardiohelp 4 (33)
Micafungin indication n (%)
Prophylaxis 11 (92)
Therapy 1 (8)
Micafungin dosing (mg/kg/day) 4 (4, 8)
Duration of therapy (days) 4 (2, 8)
Duration of ECMO support at time of
first micafungin dosing (days)
4 (2, 10)
Number of PK samples per infant 11 (6, 14)
PK samples obtained around, n (%)
Dose 1-2 12 (100)
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N=12
Dose 4-5 6 (50)
*
Results are expressed as median (range) unless otherwise specified
†
Median serum creatinine for each subject over the study period.
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Table 2
Pharmacokinetic Parameters
ID Age
(days)
Clearance
(L/kg/h)
Volume of
distribution (L/kg)
Half-life
(h)
Dose
(mg/kg/day)
AUC (mg*h/L) Albumin*
(g/dL)0-24h 72-96h
1 0 0.036 0.98 19 4 69 117 3.1
2 1 0.040 0.76 13 8 213§ 178† 3.6
3 1 0.046 0.64 10 4 72 - 2.5
4† 4 0.042 0.75 12 4 68 - 2.8
5 16 0.062 0.91 10 4 53 - 2.5
6 44 0.058 0.65 8 4 59 - 2.1
7† 74 0.026 0.56 15 4 93 163 4.2
8† 108 0.043 0.53 9 4 74 109 2.5
9 122 0.044 0.69 11 4 77 84 2.7
10 135 0.030 0.44 10 4 105 - 3.1
11 † 187 0.040 0.46 8 4 84 - 3.8
12 574 0.028 0.61 15 4 89 187** 3.7
Median
(range)
59
(0, 574)
0.041
(0.026, 0.062)
0.64
(0.44, 0.98)
11
(8, 19)
4
(4, 8) 74
‡
(53, 106)
117
‡
(84, 187)
3.0
(2.1, 4.2)
Clearance and volume of distribution estimates were determined using a one-compartmental model fitting micafungin concentrations after both 
dose 1 and 4
AUC: area under the concentration-time curve
†
Hemofilter in line
*
Median serum albumin value over the study period (from 72h prior to first study dose through 72h after last study dose)
§AUC 24-48h
†AUC 96-120h
**AUC 79-103h
‡Summary statistics do not include AUC values from subject #2
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